France-based Atlab Pharma has reported positive data from a Phase II study of ATL101 (Lutetium-177 anti-PSMA antibody), conducted in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC).

A statistically significant relationship between injected dose and antitumor activity was observed in the study, which demonstrated a favourable safety profile.

Atlab medical affairs head Professor Jean-François Chatal said the results signify the safety and the antitumor activity of ATL101 in mCRPC.

"ATL101 shows a steep dose effect on antitumor activity as expected from its radiotherapy mode of action and a potential in prolonging the life of patients with metastatic prostate cancer," Chatal said.

ATL101 was administered as a single intravenous injection at two radioactivity dose levels, 65mCi/m² or 70mCi/m², in two planned consecutive cohorts of the study enrolling 15 and 17 mCRPC patients respectively.

"A statistically significant relationship between injected dose and antitumor activity was observed in the study"

Later, a third expansion cohort of 15 patients was added at the 70mCi/m² dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the data, all patients had failed up to four hormonal therapies and 55% had also failed at least one docetaxel containing chemotherapy regimen.

An increase from 13% of patients in cohort 1 to 47% in cohort 2 achieving PSA decline over 30% was observed.

Cohort 3 also showed a 30% PSA decline in 47% of patients.

The study observed treatment effect on the circulating tumour cells (CTC) count.

The study, in which the treatment was well-tolerated, showed significant improvement in median overall survival from 11.9 months in cohort 1 to 21.8 months in cohorts 2 and 3.